Proteomic Biomarkers Are Predictive of Non-Relapse Mortality in Patients Treated with Post-Transplantation Cyclophosphamide Following HLA-Haploidentical or HLA- Matched-Related or –Unrelated Allogeneic BMT  Christopher G. Kanakry, MD, Giorgos Bakoyannis, PhD, Susan M. Perkins, PhD, Shannon R. McCurdy, MD, Edus H. Warren, MD, PhD, Ante Vulic, MD, Etienne Daguindau, MD, Taylor Olmsted, MD, Christen Mumaw, BS, Andrea M. Towlerton, BS, Paul V. O'Donnell, MD, PhD, Heather J. Symons, MD, MHS, Sophie Paczesny, MD, PhD, Leo Luznik, MD  Biology of Blood and Marrow Transplantation  Volume 22, Issue 3, Pages S325-S327 (March 2016) DOI: 10.1016/j.bbmt.2015.11.803 Copyright © 2016 Terms and Conditions

Figure 1 Plasma biomarkers measured over time. Of the seven rested biomarkers, the font leading ones based on the multivariable analyses are shown. Elevations in three of these four biomarkers were similar irrespective of donor type. Asterisks denote statistically significant differences between patients at each time point and donors. Biology of Blood and Marrow Transplantation 2016 22, S325-S327DOI: (10.1016/j.bbmt.2015.11.803) Copyright © 2016 Terms and Conditions

Figure 2 Cumulative incidences of non-relapse mortality (A) or relapse (B) stratified by median levels of four plasma bio markers. Biology of Blood and Marrow Transplantation 2016 22, S325-S327DOI: (10.1016/j.bbmt.2015.11.803) Copyright © 2016 Terms and Conditions